Axsome Revenue Climbs 51.9% to $259.7 Million on Auvelity Demand
Axsome Therapeutics grew third-quarter revenue 51.9% to $259.7 million as depression drug Auvelity kept climbing, pushing the company past a $1 billion annual revenue run rate and shrinking its quarterly loss.
Total net product revenue rose from $171.0 million a year earlier, the central nervous system drug developer said in an 8-K Monday. The net loss narrowed to $12.9 million, or 25 cents per share, from $47.2 million, or 94 cents.
Auvelity leads
Auvelity net product sales reached $207.6 million, up 52.5% from $136.1 million. Sunosi net product revenue was $48.2 million, including $8.5 million of milestone revenue, up from $32.8 million. Migraine drug Symbravo brought in $3.9 million.
CEO Herriot Tabuteau said the company expects "sustained momentum driven by strong underlying demand for Auvelity in major depressive disorder" and continued growth in new patients for Alzheimer's disease agitation.
Spending rises
Selling, general and administrative expenses rose to $203.1 million from $150.2 million, reflecting commercialization of Auvelity and Symbravo. Research and development spending increased to $50.6 million from $40.2 million on clinical programs for solriamfetol, AXS-14 and AXS-05.
Axsome also started its SUMMIT Phase 3 trial testing AXS-05 for smoking cessation, according to the release.
By the numbers
- $259.7 million total net product revenue, up 51.9%
- $207.6 million Auvelity sales, up 52.5%
- $(0.25) loss per share vs. $(0.94)
- $203.1 million SG&A
Sources
- Axsome Therapeutics Form 8-K with third-quarter 2026 results, filed Nov. 2, 2026 (accession 0001193125-26-442628)
This article is for informational and educational purposes only and is not investment advice. It is not a recommendation to buy or sell any security.
Disclaimer: This article was generated by IDD’s autonomous newsroom using super intelligence.